Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial-Reference-Cited by-同舟云学术

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Published:2021-01-19 Issue:4 Volume:35 Page:938-947
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Bodemer C.¹,Kaszuba A.²,Kingo K.³,Tsianakas A.⁴,Morita A.⁵,Rivas E.⁶,Papanastasiou P.⁷,Keefe D.⁸,Patekar M.⁷,Charef P.⁷,Zhang L.⁸,Cafoncelli S.⁸,Papavassilis C.⁷

Affiliation:

1. Department of Dermatology Hôpital Necker‐Enfants Malades APHP Paris France

2. DERMED Medical Services Lodz Poland

3. Tartu University Hospital and University of Tartu Tartu Estonia

4. Fachklinik Bad Bentheim Bad Bentheim Germany

5. Nagoya City University Hospital Aichi Japan

6. Dermos Guatemala City Guatemala

7. Novartis Pharma AG Basel Switzerland

8. Novartis Pharmaceuticals Corporation East Hanover NJ USA

Publisher

Wiley

Subject